StaphMark
Staphylococcus aureus infections (e.g., orthopedic/surgical site infections)
Key Facts
About Sabiad
Sabiad BV is a private, pre-revenue biotech company founded in 2022 (operationally active since 2019) and based in Amsterdam, Netherlands. It is commercializing over two decades of academic research into staphylococcal proteins, centered on a patented antibody (1D9) for theranostic applications. The company's core technology, StaphMark, is designed to precisely image and treat bacterial infections in real time, targeting a critical unmet need in orthopedic surgery and infectious disease. Sabiad's approach has the potential to transform infection management by enabling localized, targeted interventions that could lower healthcare costs and combat antibiotic resistance.
View full company profile